S

Sanofi

Global pharma company; vaccines and R&D

Head of SMS Program

Full-TimeUpdated on 10/15/2026Deadline 11/1/26
No salary listed
Expert
Singapore
In Person
Manufacturing & Production Operations

About the job

Requirements
  • Minimum 8 years of experience leading Operational Excellence, Lean, Six Sigma, or Continuous Improvement programs within pharmaceutical or other highly regulated manufacturing industries.
  • Proven experience leading transformation and change management initiatives.
  • Demonstrated experience deploying manufacturing operating systems and driving sustainable operational performance improvements.
  • Experience working within current Good Manufacturing Practice (cGMP)-regulated manufacturing environments.
  • Strong knowledge of Sanofi Manufacturing System (SMS) operating standards and SMS certification framework is preferred.
  • Expertise in Operational Excellence methodologies, including Lean Manufacturing, Six Sigma, Agile, and Continuous Improvement.
  • Strong understanding of manufacturing financial performance, including Profit & Loss, Gross Margin, Cost of Goods Sold (COGS), Business Operating Income (BOI), cash flow, and project portfolio management.
  • Knowledge of performance management methodologies and tools, including 3P and Shine.
  • Good understanding of data management and digital products supporting SMS operating standards, including eOEE, FaCT, and iObeya.
  • Strong project management, stakeholder management, and communication skills.
  • Good understanding of cGMP requirements and pharmaceutical manufacturing processes.
Responsibilities
  • Lead the deployment and continuous evolution of the Sanofi Manufacturing System (SMS 2.0) across the site.
  • Drive performance transformation initiatives, including SMS deployment, performance boosters, continuous improvement programs, and Factory 4.0 solutions.
  • Identify operational performance gaps through benchmarking, maturity assessments, and data-driven analysis, translating insights into improvement opportunities.
  • Ensure performance initiatives deliver measurable business impact across Quality, Delivery, Cost, Safety, and People objectives.
  • Lead change management activities to embed sustainable operational excellence practices across the organization.
  • Establish governance to monitor initiative progress, benefits realization, and long-term sustainability.
  • Drive value realization by partnering with Finance, Operations, and Procurement to validate and capture savings generated through transformation initiatives.
  • Monitor performance indicators and proactively identify risks requiring corrective actions.
  • Ensure continuous improvement initiatives are standardized, sustained, and replicated where applicable across the manufacturing organization.
  • Partner with Global SMS ecosystem leaders to develop, deploy, and continuously improve SMS operating standards.
  • Support Manufacturing & Supply network initiatives, including SMS Maturity Assessments, SMS Trainer activities, and cross-site knowledge sharing.
  • Lead the site's SMS capability-building strategy by developing structured upskilling roadmaps and continuous learning programs.
  • Foster a culture of operational excellence through coaching, mentoring, and capability development at all organizational levels.
  • Manage resource allocation for performance and transformation initiatives.
  • Oversee the site digital budget supporting SMS deployment and Factory 4.0 initiatives.
  • Define execution approaches for operational excellence programs and transformation initiatives.
  • Establish expected value creation targets and confirm realization of business benefits.
  • Lead the development of the site's SMS capability roadmap.
  • Drive periodic reviews and annual upgrades of SMS operating standards in partnership with Global Manufacturing & Supply teams.
Desired Qualifications
  • Strong knowledge of Sanofi Manufacturing System (SMS) operating standards and SMS certification framework.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)